July 1 (Reuters) - Cue Biopharma Inc CUE.O:
CUE BIOPHARMA PROVIDES UPDATE ON MOST ADVANCED CLINICAL STAGE ASSET, CUE-101, PRESENTED BY DR. DIMITRIOS COLEVAS AT THE DAVA 4TH HAWAII GLOBAL SUMMIT ON THORACIC MALIGNANCIES
CUE BIOPHARMA INC - ORR OF 50% IN HPV+ R/M HNSCC PATIENTS
CUE BIOPHARMA INC - 12-MONTH SURVIVAL OF 88% AND MOS OF 32 MONTHS